General
Preferred name
SERTINDOLE
Synonyms
Sertindol ()
Lu 23-174 ()
LU-23-174 ()
Serdolect ()
LU 23-174 ()
Serlect ()
Zerdol ()
P&D ID
PD009327
CAS
106516-24-9
Tags
available
drug
Approved by
MHRA
First approval
1996
Drug indication
Schizophrenia
Psychosis
Drug Status
approved
withdrawn
investigational
Max Phase
4.0
Probe control
Probe control not defined
Orthogonal probes
0
No orthogonal probes found
Similar probes
0
No structurally similar probes found
Structure
P&D probe-likeness score
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION
Sertindole is an atypical antipsychotic medication, functioning as a dopamine D2 and serotonin 5-HT2 receptor antagonist.
(GtoPdb)
DESCRIPTION
Sertindole (Lu 23-174) is an orally active 5-HT2A, 5-HT2C, dopamine D2, and ¦Ál-adrenergic receptors antagonist. Sertindole shows antipsychotic activity and anti-proliferative activity to multiple cancer cells[1][2][3].
PRICE
55
DESCRIPTION
Sertindole, a neuroleptic, is one of the newer antipsychotic medications available.
(BOC Sciences Bioactive Compounds)
DESCRIPTION
Sertindole (Lu 23-174) is an atypical antipsychotic that binds to dopamine D2 receptors and serotonin (5-HT) receptor subtypes 5-HT1D, 5-HT2A, and 5-HT2C, with Kds of 2.7, 20, 0.14, and 6 nM, respectively.
(TargetMol Bioactive Compound Library)
[[ p.pathway_name ]]
[[ compound.targets[tid].gene_name ]]
Compound Sets
28
Axon Medchem Screening Library
BOC Sciences Bioactive Compounds
Cayman Chemical Bioactives
ChEMBL Approved Drugs
ChEMBL Drugs
Concise Guide to Pharmacology 2017/18
Concise Guide to Pharmacology 2019/20
Concise Guide to Pharmacology 2021/22
Concise Guide to Pharmacology 2023/24
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DrugBank Approved Drugs
DrugCentral
DrugCentral Approved Drugs
DrugMAP
DrugMatrix
EU-OPENSCREEN Bioactive Compound Library
Guide to Pharmacology
Ki Database
LSP-MoA library (Laboratory of Systems Pharmacology)
MedChem Express Bioactive Compound Library
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
TargetMol Bioactive Compound Library
Withdrawn 2.0
[[ a.name ]]
[[ ligand_id ]]
free of charge
External IDs
36
Molecular Weight
440.18
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
1
Rotatable Bonds
5
Ring Count
5
Aromatic Ring Count
3
cLogP
4.63
TPSA
40.51
Fraction CSP3
0.38
Chiral centers
0.0
Largest ring
6.0
QED
0.63
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Pathway
Autophagy
GPCR/G protein
Neuroscience
Neuronal Signaling
Member status
member
MOA
5-HT2A Antagonists
Dopamine D2 Antagonists
dopamine receptor antagonist, serotonin receptor antagonist
Target
ADRA1A, ADRA1B, ADRA1D, DRD2, DRD3, DRD4, HRH1, HTR1A, HTR1B, HTR1D, HTR1E, HTR1F, HTR2A, HTR2C, HTR6, KCNH2
Antipsychotic
5-HT Receptor
Adrenergic Receptor
Dopamine Receptor
5-HT
D2
dopamine
ATC
N05AE03
Toxicity type
cardiovascular
Therapeutic Class
Antipsychotic Agents
Source data
